Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp96 | Diabetes Therapy | ECE2018

Long term results and determinants of outcomes in primary health care diabetes prevention. The DE-PLAN project

Gilis-Januszewska Aleksandra , Lindstrom Jaana , Barengo Noel C , Tuomilehto Jaakko

Background: Real life implementation studies performed in different settings/populations proved that lifestyle interventions in prevention of DM2 can be effective. However, little is known about long term results of these translational studies and determinants of the outcomes.Aim: The purpose of this study was to examine the maintenance of diabetes type 2 risk factor during 3 year follow-up and to examine determinants of long term outcomes.<p class="...

ea0081p595 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Somatostatin analogue treatment for hyperinsulinemic hypoglycemia with glucokinase activating mutation (GCK), c.295T>C (p.Trp99Arg)

Boguslawska Anna , Rzepka Ewelina , Kluczyński Lukasz , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Somatostatin analogues (SSA) are used to treat different forms of hyperinsulinemic hypoglycemia (HH) in children and adults and therapeutic effect is achieved by suppressing insulin secretion from pancreatic β-cells by complex mechanisms. These treatments might be associated with several side effects, can even cause the worsening of severity of hypoglycemia. This is a report of the treatment of HH with SSA in patient with Activating Mutation (GCK), c.295T>C (p.Trp99Ar...

ea0070aep599 | Pituitary and Neuroendocrinology | ECE2020

Midparental height is an important predictive parameter in a late diagnosis of acromegaly and gigantism in adults. Single centre, pilot study

Bogusławska Anna , Gilis-Januszewska Aleksandra , Godlewska Magdalena , Olszewska Marta , Hubalewska-Dydejczyk Alicja , Starzyk Jerzy

Introduction: Acromegaly is a rare disorder caused by excessive growth hormone production. Common clinical manifestations are visual changes as well as serious systemic complications. In childhood and adolescence, excessive growth hormone production leads to abnormal tall stature. To date, only a few studies have been published focusing on analysing the growth of patients with acromegaly, in particular regarding the growth of their parents and siblings. A&#...

ea0032p367 | Diabetes | ECE2013

Progression to impaired glucose metabolism in normal glucose tolerant urban population

Piorowska Natalia , Gilis-Januszewska Aleksandra , Piwonska-Solska Beata , Szafraniec Krystyna , Pach Dorota , Hubalewska-Dydejczyk Alicja

Objective: To determine the progression rate to impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes (DM2) and risk factors of progression to diabetes in normal glucose tolerant (NGT) people during 8 years follow up study using WHO 1999 criteria and new criteria of IFG (IFG 5.6-fasting glucose 5.6–6.9 mmol/l).Research design and methods: This is an 8 year prospective observation in a randomly selected urban population aged ...

ea0073aep472 | Pituitary and Neuroendocrinology | ECE2021

Age and sex differences among patients with acromegaly

Anna Boguslawska , Gilis-Januszewska Aleksandra , Godlewska Magdalena , Nowak Andrzej , Starzyk Jerzy , Hubalewska-Dydejczyk Alicja

IntroductionAcromegaly is a chronic, slowly progressing disease caused in most cases by growth hormone (GH)- producing pituitary neuroendocrine tumors (PitNETs). This rare disorder is associated with a spectrum of various clinical manifestations and treatment outcomes differ between patients. The aim of this study was to evaluate the impact of age at the onset of symptoms and sex on clinical features, comorbidities, biochemical status at the diagnosis, a...

ea0081p177 | Pituitary and Neuroendocrinology | ECE2022

Use of corrected SUVmax as a prognostic indicator of response to PRRT

Opalinska Marta , Sowa-Staszczak Anna , Kania-Kuc Adrian , Al Maraih Ibraheem , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Background: PRRT is an effective treatment option (especially for controlling disease progression)for disseminated neuroendocrine tumors (NETs), with good expression of the somatostatin receptors. Despite significant progress in NET personalized management, searching for novel predictive and prognostic factors of response to PRRT is crucial for more effective follow-up, better treatment choices leading to more favorable final outcome. Some recent studies indicate that the resp...

ea0081p690 | Pituitary and Neuroendocrinology | ECE2022

Clinical characteristics at diagnosis and diagnostic delay among newly-diagnosed patients with acromegaly- single-center, pilot study

Godlewska Magdalena , Bogusławska Anna , Kluczyński Łukasz , Rzepka Ewelina , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Diagnostic delay remains significant among the patients with acromegaly, even though the disease awareness has improved over the years.Aim: The aim was to investigate the diagnostic delay and symptoms present at diagnosis of acromegaly among the newly-diagnosed patients.Material and methods: 72 consecutive patients diagnosed with acromegaly between 01.2014 and 12.2021 were evaluated. Division into groups based on: gen...

ea0081p693 | Pituitary and Neuroendocrinology | ECE2022

Multimodal treatment including temozolomide (TMZ) and pasireotide for aggressive, giant silent corticotroph PiTNET in a young patient

Bogusławska Anna , Kluczyński Łukasz , Godlewska Magdalena , Rzepka Ewelina , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Silent corticotroph pituitary neuroendocrine tumours (PiTNETs) are a subtype of nonfunctioning PiTNETs, that present positive immunostaining for adrenocorticotropin (ACTH) and/or show the expression of the transcription factor T-PIT without clinical signs of hypercortisolemia. They constitute 20% of all corticotroph PitNETs and manifest in most cases as macroadenoma with suprasellar extension and a higher tendency to apoplexy. We present a 33-year-old male with aggressive cour...

ea0081ep701 | Pituitary and Neuroendocrinology | ECE2022

Age at the diagnosis or age at the onset of symptoms- which should be taken into consideration in patients with early-onset acromegaly- pilot study

Godlewska Magdalena , Bogusławska Anna , Kluczyński Łukasz , Rzepka Ewelina , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: The group of young adults with acromegaly, despite initial reports about their aggressive course of disease, has not been thoroughly characterized. Aim: Our aim was to investigate the differences between the patients with early-onset acromegaly and with onset in older age. Material and methods: Consecutive patients diagnosed with acromegaly between 01.2014 and 12.2021 were included in this retrospective study, approve...

ea0081ep727 | Pituitary and Neuroendocrinology | ECE2022

Challenging management of giant prolactinomas in men: from efficient small dose of cabergoline to SSA, neurosurgery and Temozolomide

Gilis-Januszewska Aleksandra , Bogusławska Anna , Godlewska Magdalena , Kluczyński Łukasz , Hubalewska-Dydejczyk Alicja

Giant prolactinomas are very rare and constitute 2-3% of all lactotroph PitNETs with male preponderance. We present a case series of five male patients with giant prolactinomas with various clinical presentation. Case 1: A 66-year-old male hospitalized due to left peripheral facial palsy. In computer tomography (CT) pituitary mass (41 x 43 x 64 mm) invading cavernous/sphenoid sinuses/carotid arteries/optic chiasm was visualized. Bitemporal hemianopia/hea...